Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner. Smart investors know one truth holds steady: reliable income beats hype every time.
That is why you should consider owning a healthcare giant that has raised its dividend through recessions, pandemics, and patent cliffs — without missing a beat. Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a Dividend King that doesn’t just pay; it delivers consistency that lets shareholders sleep soundly while the broader market twists.
A Dividend Legacy Built on 63 Years of Increases
Johnson & Johnson has hiked its dividend for 63 consecutive years, and stands poised to deliver its 64th annual increase when it reports first-quarter 2026 earnings before the market opens on April 14. That track record isn’t luck — it’s the result of disciplined capital allocation across its diversified portfolio of medicines, medical devices, and consumer health products.
Last year, Johnson & Johnson raised its quarterly payout from $1.24 to $1.30 per share, a near-5% increase. The stock now yields 2.14% at an annualized $5.20 per share. Over the past decade, it has delivered 5% compounded annual growth. The payout ratio also sits at a comfortable 46.7%, leaving ample room for reinvestment or further hikes. In short, this isn’t a high-yield trap—it’s a machine built for steady raises for decades to come.
Financial Results That Speak Louder Than Headlines
Let’s look at the numbers that back this up. Johnson & Johnson’s full-year 2025 results showed reported sales of $94.2 billion, up 6% from 2024. Operational growth hit 5.3%, even after accounting for the loss of exclusivity on Stelara. Innovative Medicine alone topped $60 billion in sales for the first time, with 13 brands growing double digits.
Adjusted earnings reached $10.79 per share, an 8.1% increase from the prior year. Free cash flow came in at approximately $19.7 billion, funding $12.4 billion in dividends paid to shareholders and more than $32 billion in R&D plus strategic acquisitions. The balance sheet remains fortress-strong, with net debt around $28 billion against nearly $20 billion in cash and marketable securities.
No matter how you look at it, these figures show a company that generates cash it can afford to share — without stretching.
Stability Wins Out Versus Peers
Investors often chase higher yields elsewhere in healthcare, but Johnson & Johnson stacks up favorably when you compare the full picture. Here’s how it lines up against two key rivals, based on the latest available data:
| Metric | Johnson & Johnson | Pfizer (NYSE:PFE) | Merck (NYSE:MRK) |
| Dividend Yield | 2.14% | 6.20% | 2.88% |
| Payout Ratio | 46.7% | 118.6% | 45.8% |
| Consecutive Dividend Increases | 63 years | 16 years | 15 years |
| 5-Year Average Annual Dividend Growth | 5.25% | 2.5% | 7% |
Pfizer’s sky-high yield comes with real risk — its payout ratio above 100% signals pressure ahead. Merck offers solid growth but lacks Johnson & Johnson’s breadth and decades-long reliability. Johnson & Johnson also trades at a normalized P/E of about 22.45, a reasonable premium for its lower volatility and proven cash generation.
That said, no stock is risk-free. Ongoing litigation and patent expirations remain watch items, but Johnson & Johnson’s diversified pipeline — 28 platforms now generating over $1 billion annually — positions it to navigate those challenges.
Key Takeaway
Don’t bet against this Dividend King. With earnings due April 14 and the 64th dividend increase on the horizon, Johnson & Johnson offers retail investors a rare combination: 2.14% yield today, low payout ratio for future growth, and a business model built to compound wealth quietly. Add it for the income and the peace of mind — your portfolio will thank you.
Top Gaining Stocks
Top Losing Stocks